Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life
Background & Aims. The article presents results of two observational, prospective, multicenter studies “Quality of Life, Symptom Profile, and Adherence to Treatment in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Receiving Dasatinib” (2012–2015) and “Quality of Life...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2017-04-01
|
| Series: | Клиническая онкогематология |
| Subjects: | |
| Online Access: | http://bloodjournal.ru/wp-content/uploads/2017/03/10.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850152515485564928 |
|---|---|
| author | TI Ionova NB Bulieva OYu Vinogradova TA Gritsenko LK Kozlova GB Kuchma EG Lomaia ER Machyulaitene TP Nikitina NV Novitskaya AYu Rodionova EI Usacheva TV Shneider |
| author_facet | TI Ionova NB Bulieva OYu Vinogradova TA Gritsenko LK Kozlova GB Kuchma EG Lomaia ER Machyulaitene TP Nikitina NV Novitskaya AYu Rodionova EI Usacheva TV Shneider |
| author_sort | TI Ionova |
| collection | DOAJ |
| description | Background & Aims. The article presents results of two observational, prospective, multicenter studies “Quality of Life, Symptom Profile, and Adherence to Treatment in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Receiving Dasatinib” (2012–2015) and “Quality of Life and Symptom Profile in Imatinib-Resistant or Intolerant Patients with Chronic Myeloid Leukemia” (2011–2014).
Methods. Data of 107 patients with chronic myeloid leukemia in chronic phase were involved in the real-world analysis — 32 newly diagnosed patients on first-line treatment with dasatinib or after yearly switch to dasatinib after imatinib treatment failure and 75 imatinib-resistant or intolerant patients on second-line treatment with dasatinib. Treatment effectiveness and safety of dasatinib were assessed during first and second-line dasatinib treatment using clinical outcomes as well as quality of life and symptom profile assessment.
Results. The real-world data obtained during observational study in limited population of CML patients conform the results of clinical trials devoted to evaluation of treatment efficacy and safety of dasatinib treatment in first and second-line treatment and demonstrate the importance of patient-reported outcomes. Patient’s quality of life improved within 12 months of the first-line dasatinib therapy according to the following scales: role physical functioning, pain, vitality, social functioning and role emotional functioning. The most pronounced and clinically significant improvement was observed for the role emotional functioning (51.1 vs. 68.9). During the second-line dasatinib treatment, stabilization of quality of life parameters was registered for the following scales: vitality, social functioning, mental health, and pain. Significant improvement of the Integral Quality of Life Index was observed (p < 0.05). Positive dynamics of relevant symptoms was registered. The symptom severity decreased during both the first and second-line therapy.
Conclusion. Quality of life and symptom assessment in CML patients contribute to a better disease control in accordance with the principles of risk-adaptive therapy. |
| format | Article |
| id | doaj-art-0a04d657d14d4a4f94ccc50e348addb6 |
| institution | OA Journals |
| issn | 1997-6933 2500-2139 |
| language | Russian |
| publishDate | 2017-04-01 |
| publisher | Practical Medicine Publishing House |
| record_format | Article |
| series | Клиническая онкогематология |
| spelling | doaj-art-0a04d657d14d4a4f94ccc50e348addb62025-08-20T02:25:58ZrusPractical Medicine Publishing HouseКлиническая онкогематология1997-69332500-21392017-04-0110220621710.21320/2500-2139-2017-10-2-206-217Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of LifeTI Ionova0NB Bulieva1OYu Vinogradova2TA Gritsenko3LK Kozlova4GB Kuchma5EG Lomaia6ER Machyulaitene7TP Nikitina8NV Novitskaya9AYu Rodionova10EI Usacheva11TV Shneider12Saint Petersburg Multifield Medical Center under the Ministry of Health of Russia, 154 Nabereznaya Reki Fontanki, Saint Petersburg, Russian Federation, 198103; Multinational Center for Quality of Life Research, 1 Artilleriiskaya str., office 152, Saint Petersburg, Russian Federation, 191014I Kant Baltic Federal University, 14 A Nevskogo str., Kaliningrad, Russian Federation, 236041SP Botkin Municipal Clinical Hospital, 5 2-i Botkinskii pr-zd, Moscow, Russian Federation, 125284; Dmitrii Rogachev Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology under the Ministry of Health of the Russian Federation, 1 Samory Mashela str., Moscow, Russian Federation, 117198; NI Pirogov Russian National Research Medical University under the Ministry of Health of the Russian Federation, 1 Ostrovityanova str., Moscow, Russian Federation, 117997Samara State Medical University under the Ministry of Health of the Russian Federation, 89 Chapaevskaya str., Samara, Russian Federation, 443099Orenburg State Medical University, 6 Sovetskaya str., Orenburg, Russian Federation, 460000Orenburg State Medical University, 6 Sovetskaya str., Orenburg, Russian Federation, 460000Federal Almazov North-West Medical Research Centre, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341Outpatient Department, Academician IP Pavlov First St. Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022Saint Petersburg Multifield Medical Center under the Ministry of Health of Russia, 154 Nabereznaya Reki Fontanki, Saint Petersburg, Russian Federation, 198103; Multinational Center for Quality of Life Research, 1 Artilleriiskaya str., office 152, Saint Petersburg, Russian Federation, 191014SP Botkin Municipal Clinical Hospital, 5 2-i Botkinskii pr-zd, Moscow, Russian Federation, 125284Multinational Center for Quality of Life Research, 1 Artilleriiskaya str., office 152, Saint Petersburg, Russian Federation, 191014RM Gorbacheva Scientific Research Institute of Pediatric Hematology and Transplantation; Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022Leningrad District Clinical Hospital, 43/49 Lunacharskogo pr-t, Saint Petersburg, Russian Federation, 194291Background & Aims. The article presents results of two observational, prospective, multicenter studies “Quality of Life, Symptom Profile, and Adherence to Treatment in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Receiving Dasatinib” (2012–2015) and “Quality of Life and Symptom Profile in Imatinib-Resistant or Intolerant Patients with Chronic Myeloid Leukemia” (2011–2014). Methods. Data of 107 patients with chronic myeloid leukemia in chronic phase were involved in the real-world analysis — 32 newly diagnosed patients on first-line treatment with dasatinib or after yearly switch to dasatinib after imatinib treatment failure and 75 imatinib-resistant or intolerant patients on second-line treatment with dasatinib. Treatment effectiveness and safety of dasatinib were assessed during first and second-line dasatinib treatment using clinical outcomes as well as quality of life and symptom profile assessment. Results. The real-world data obtained during observational study in limited population of CML patients conform the results of clinical trials devoted to evaluation of treatment efficacy and safety of dasatinib treatment in first and second-line treatment and demonstrate the importance of patient-reported outcomes. Patient’s quality of life improved within 12 months of the first-line dasatinib therapy according to the following scales: role physical functioning, pain, vitality, social functioning and role emotional functioning. The most pronounced and clinically significant improvement was observed for the role emotional functioning (51.1 vs. 68.9). During the second-line dasatinib treatment, stabilization of quality of life parameters was registered for the following scales: vitality, social functioning, mental health, and pain. Significant improvement of the Integral Quality of Life Index was observed (p < 0.05). Positive dynamics of relevant symptoms was registered. The symptom severity decreased during both the first and second-line therapy. Conclusion. Quality of life and symptom assessment in CML patients contribute to a better disease control in accordance with the principles of risk-adaptive therapy.http://bloodjournal.ru/wp-content/uploads/2017/03/10.pdfquality of lifechronic myeloid leukemiadasatinibtherapy effectivenesstherapy safetyroutine clinical practice |
| spellingShingle | TI Ionova NB Bulieva OYu Vinogradova TA Gritsenko LK Kozlova GB Kuchma EG Lomaia ER Machyulaitene TP Nikitina NV Novitskaya AYu Rodionova EI Usacheva TV Shneider Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life Клиническая онкогематология quality of life chronic myeloid leukemia dasatinib therapy effectiveness therapy safety routine clinical practice |
| title | Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life |
| title_full | Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life |
| title_fullStr | Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life |
| title_full_unstemmed | Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life |
| title_short | Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life |
| title_sort | dasatinib in first and second line therapy of chronic myeloid leukemia efficacy safety and quality of life |
| topic | quality of life chronic myeloid leukemia dasatinib therapy effectiveness therapy safety routine clinical practice |
| url | http://bloodjournal.ru/wp-content/uploads/2017/03/10.pdf |
| work_keys_str_mv | AT tiionova dasatinibinfirstandsecondlinetherapyofchronicmyeloidleukemiaefficacysafetyandqualityoflife AT nbbulieva dasatinibinfirstandsecondlinetherapyofchronicmyeloidleukemiaefficacysafetyandqualityoflife AT oyuvinogradova dasatinibinfirstandsecondlinetherapyofchronicmyeloidleukemiaefficacysafetyandqualityoflife AT tagritsenko dasatinibinfirstandsecondlinetherapyofchronicmyeloidleukemiaefficacysafetyandqualityoflife AT lkkozlova dasatinibinfirstandsecondlinetherapyofchronicmyeloidleukemiaefficacysafetyandqualityoflife AT gbkuchma dasatinibinfirstandsecondlinetherapyofchronicmyeloidleukemiaefficacysafetyandqualityoflife AT eglomaia dasatinibinfirstandsecondlinetherapyofchronicmyeloidleukemiaefficacysafetyandqualityoflife AT ermachyulaitene dasatinibinfirstandsecondlinetherapyofchronicmyeloidleukemiaefficacysafetyandqualityoflife AT tpnikitina dasatinibinfirstandsecondlinetherapyofchronicmyeloidleukemiaefficacysafetyandqualityoflife AT nvnovitskaya dasatinibinfirstandsecondlinetherapyofchronicmyeloidleukemiaefficacysafetyandqualityoflife AT ayurodionova dasatinibinfirstandsecondlinetherapyofchronicmyeloidleukemiaefficacysafetyandqualityoflife AT eiusacheva dasatinibinfirstandsecondlinetherapyofchronicmyeloidleukemiaefficacysafetyandqualityoflife AT tvshneider dasatinibinfirstandsecondlinetherapyofchronicmyeloidleukemiaefficacysafetyandqualityoflife |